Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneering medtech company focused on nerve-targeted diagnostics and therapies, has been granted a U.S. patent (No. 12,279,889 B2) for its innovative catheter-based nerve-sensing and ablation technology. This marks a major milestone for the company as it continues to expand its intellectual property portfolio and progress toward commercialization.
✅ Cutting-Edge Technology Targeting Hard-to-Treat Conditions
The newly patented device combines microchip sensing arrays, microneedle sensors, optical sensors, and unique microfingers to accurately detect, map, and monitor nerve activity. It is specifically designed to locate small nerves in and around blood vessels and capture real-time electrophysiological signals before, during, and after neuromodulation or radiofrequency (RF) ablation.
This proprietary technology is aimed at addressing a range of serious health conditions linked to overactive sympathetic nervous activity, such as:
Chronic pain (including pancreatic cancer-related pain)
Hypertension
Cardiovascular diseases
Metabolic disorders
Certain neurological conditions
Autonomix’s platform may represent a transformative solution in nerve modulation, with the potential to reduce dependency on opioid-based treatments.
🧪 Next Phase: Clinical Trials in the U.S.
Backed by promising Phase I clinical data demonstrating substantial pain relief and reduced opioid use, Autonomix plans to file for an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA). Clinical trials in the United States are scheduled to commence in 2025, with an initial focus on treating pancreatic cancer pain.
While the device is still under investigation and not yet approved for commercial use, these developments underscore its strong potential in a multi-billion-dollar market.
🔒 Strengthened Intellectual Property Portfolio
The issuance of this U.S. patent significantly enhances Autonomix’s competitive standing. The company now holds over 80 patents worldwide, signaling its stronghold in the emerging market of catheter-based nerve therapies. The patent provides exclusive protection in the U.S. for its sensing and ablation system, supporting future licensing opportunities and strategic partnerships.
📉 Financial & Market Context
Despite recent market challenges—Autonomix shares have declined over 65% year-to-date—the company maintains a robust liquidity position and continues to invest in research and development. This patent milestone could serve as a catalyst for investor confidence as the company approaches critical clinical and regulatory phases.
🔍 Key Highlights
Feature Details
Patent No. US 12,279,889 B2
Technology Nerve-sensing + RF ablation catheter system
Clinical Use (Planned) Chronic pain, hypertension, cardiac, metabolic, neuro disorders
Clinical Trial Timeline IDE submission in 2025; U.S. trials to follow
Current Status Investigational; not FDA approved
IP Strength Over 80 patents issued global
📌 Disclaimer
This article is for informational purposes only.